Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Drones Spotted Near Zelenskiy’s Flight Path in Ireland Trigger Security Alert 
California Launches Portal for Reporting Alleged Misconduct by Federal Immigration Agents 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
UN General Assembly Demands Russia Return Ukrainian Children Amid Ongoing Conflict 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
U.S.-Russia Talks Leave Ukraine Peace Efforts Uncertain 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Trump Administration Tightens H-1B Visa Vetting With New Focus on Free Speech and Censorship 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
President Donald Trump has announced a new agreement with UK-based pharmaceutical giant AstraZeneca, following a similar deal with Pfizer, aimed at cutting prescription drug prices in the United States. Under the pact, AstraZeneca will provide certain medicines to the U.S. Medicaid health program at discounted rates in exchange for relief from import tariffs, marking another step in the administration’s push to lower healthcare costs.
The deal forms part of the White House’s broader strategy to pressure major drugmakers to align U.S. prices with those in other developed nations, where patients often pay nearly three times less. In July, Trump sent letters to 17 leading pharmaceutical companies urging them to reduce prices or face steep tariffs. AstraZeneca and Pfizer are the first to comply, setting the stage for future negotiations.
AstraZeneca CEO Pascal Soriot revealed that the company will offer select drugs at up to 80% off their list prices through the upcoming TrumpRx online platform. In return, the firm will receive a three-year tariff exemption to support its plan to localize more of its production in the U.S. Soriot emphasized AstraZeneca’s growing American footprint, noting a $50 billion investment in U.S. manufacturing and R&D by 2030, including a massive new site in Virginia.
While the initiative may ease costs for Medicaid, experts remain skeptical about its broader impact. Northwestern University professor Craig Garthwaite noted that Medicaid already benefits from the nation’s lowest drug prices, suggesting limited savings. Boston University’s Rena Conti added that while the agreement benefits pharmaceutical firms, it offers little relief to Americans struggling with high out-of-pocket costs.
AstraZeneca’s latest moves reflect its effort to strengthen ties with Washington while expanding U.S. operations, including plans to list its shares on U.S. markets and sell some drugs directly to cash-paying patients at significant discounts.
